You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 873 ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
873 ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address